For research and educational purposes only. Not intended for human consumption.
Thymosin Alpha 1
Extensively Studied- •Cancer immunotherapy: T cells 422→614/μL
- •NSCLC survival improvement data
- •2025 pancreatitis meta-analysis
Synthetic Thymic Hormone | Immune System Modulation
Overview
What is Thymosin Alpha 1?
Thymosin Alpha 1 (Ta1/Thymalfasin/Zadaxin) is a synthetic 28-amino acid peptide identical to the naturally occurring thymic hormone. 2024-2025 research shows significant promise in cancer immunotherapy: in advanced solid tumor patients, a 7-day loading dose increased total T cells from 422.5/μL to 614.0/μL (P<0.001), with CD4+ and CD8+ T cells also significantly elevated. Approved in 35+ countries with <1% serious adverse events across 11,000+ patients.
Key Benefits
Primary FDA-studied route with extensive clinical data. 2024-2025 cancer research shows enhanced lymphocyte recovery, improved immunotherapy eligibility, and survival trends when combined with chemoradiotherapy. Enhanced vaccine responses in elderly/hemodialysis patients. Multiple ongoing trials (NCT06821100, NCT06598839).
Mechanism of Action
Injectable Ta1 provides optimal bioavailability (90-95%) with rapid Tmax of 2 hours. Activates multiple TLR pathways, enhances T-cell maturation (CD4+, CD8+), stimulates NK cells, and modulates dendritic cell function. 2025 meta-analysis confirms increased CD4+ percentages and CD4+/CD8+ ratios in severe acute pancreatitis.
Molecular Information
Pharmacokinetics
Research Indications
Primary Immunodeficiencies
FDA orphan drug designation for DiGeorge syndrome with documented restoration of T-cell function.
Vaccine Response Enhancement
Enhances immunogenicity in elderly and hemodialysis patients with improved antibody responses.
HIV/AIDS Immune Support
Restores CD4+ T-cell counts and reduces opportunistic infections in HIV patients.
Research Protocols
Disclaimer: Thymosin Alpha 1 is approved in 35+ countries. These protocols are based on clinical research. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Standard immune support | 1.6mg | 2x weekly | SubQ |
| Acute conditions (sepsis) | 1.6mg | 2x daily × 5 days, then daily | SubQ or IM |
| Cancer/hepatitis support | 1.6mg | 2x weekly | SubQ |
| Maintenance/prevention | 1.6mg | 2x weekly | SubQ |
Timing: Injectable Ta1 can be administered at any time. Maintain consistent twice-weekly schedule (e.g., Monday/Thursday). Rotate injection sites to prevent tissue irritation.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Clean work area and hands thoroughly
Add 1.0 mL sterile water slowly to lyophilized powder
Inject water slowly down vial side (not directly onto powder)
Gently swirl until completely dissolved (never shake)
Final concentration: 1.6 mg/mL
Use promptly or refrigerate at 2-8°C for up to 7 days
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
White Lyophilized Powder
Properly freeze-dried Ta1 appears as white, fluffy powder.
Clear Solution After Reconstitution
When mixed with sterile water, solution should be crystal clear.
Proper Pharmaceutical Labeling
Vials should have clear labeling with batch numbers and expiration dates.
Minor Powder Compaction
Slight compaction during shipping is acceptable if powder dissolves completely.
Discolored or Collapsed Powder
Yellow, brown, or collapsed powder indicates degradation.
Persistent Cloudiness
Solution remains cloudy indicates degraded product.
What to Expect
- •Week 1-2: Initial immune system activation
- •Week 2-6: Enhanced immune function and reduced infection risk
- •Week 6-12: Maximum immunomodulatory benefits
- •Week 12+: Sustained immune support with continued use
- •Most effective for: Immune deficiencies, chronic infections, vaccine enhancement
Side Effects & Safety
Side Effects
- •Exceptional safety profile with <1% serious adverse events across 11,000+ patients
- •Most common side effect: mild injection site reactions (<10%)
- •Contraindicated in organ transplant recipients (risk of graft rejection)
- •Monitor for hypersensitivity reactions with first dose
- •Not recommended during pregnancy or breastfeeding
When to Stop
- •Signs of transplant rejection
- •Severe allergic reactions
- •Unexpected immune responses
- •As directed by physician
- •Before organ transplant
References
5 StudiesAdvanced Solid Tumors + Immunotherapy (2024-2025)
Human | 7-day loading dose + RT/immunotherapy | T cells: 422.5→614.0/μL, CD4+: 244.5→284.5/μL, CD8+: 159→222.5/μL (all P<0.001)
Retrospective analysis showed Ta1 loading dose with radiotherapy and immunotherapy significantly boosted peripheral blood T cells, CD4+, and CD8+ cells, linked to improved safety and survival trends.
Unresectable LA-NSCLC Survival Study (2024)
Human | Long-term Ta1 + CCRT + immunotherapy | Improved survival, reduced pneumonitis
Long-term Ta1 integration with concurrent chemoradiotherapy improved survival, reduced grade ≥2 pneumonitis, and accelerated lymphocyte recovery compared to short-term use.
ICI-Treated Low Lymphocyte Patients (2023)
Human | Loading-dose | Advanced solid tumors | CD3+ <0.5×10^9/L | 19.6 vs 3.9 month median OS trend
Loading-dose regimen significantly boosted CD3+, CD4+, CD8+, and NK cells, with subgroups showing ≥30% lymphocyte increase trending toward longer survival, no grade ≥3 adverse events.
Quick Start Guide
Research Disclaimer
Thymosin Alpha 1 is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving Thymosin Alpha 1 must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of Thymosin Alpha 1 for any purpose. Consult qualified professionals for any research applications.